BRIEF published on 04/28/2026 at 22:00, 4 months 13 days ago Piramal Pharma Limited publie ses résultats financiers pour l'exercice 2026 Investissement Stratégique Baisse Des Revenus Croissance Du Segment Piramal Pharma Limited Résultats Financiers 2026
BRIEF published on 04/28/2026 at 21:05, 4 months 13 days ago VAT Group AG Shareholders Approve Board Proposals and 12% Dividend Increase Dividend Increase VAT Group AG Shareholder Resolutions Board Re-elections AGM 2026
BRIEF published on 04/28/2026 at 21:05, 4 months 13 days ago Les actionnaires de VAT Group AG approuvent les propositions du conseil d'administration et une augmentation de 12 % du dividende. Réélections Du Conseil D'administration Résolutions Des Actionnaires Augmentation Des Dividendes Groupe TVA AG Assemblée Générale Annuelle 2026
BRIEF published on 04/28/2026 at 20:40, 4 months 13 days ago GenSight Biologics annonce son Assemblée Générale Mixte de 2026 Actionnaires Assemblée Générale Documents Préparatoires Thérapie Génique GenSight Biologics
BRIEF published on 04/28/2026 at 20:40, 4 months 13 days ago GenSight Biologics Schedules Annual General Meeting for May 2026 Annual General Meeting Regulatory Compliance Shareholder Information Investor Relations Gene Therapy
BRIEF published on 04/28/2026 at 20:40, 4 months 13 days ago GenSight Biologics announces its 2026 Combined General Meeting Shareholders Gene Therapy General Assembly Preparatory Documents GenSight Biologics
BRIEF published on 04/28/2026 at 20:40, 4 months 13 days ago GenSight Biologics programme son assemblée générale annuelle pour mai 2026 Conformité Réglementaire Assemblée Générale Annuelle Thérapie Génique Relations Avec Les Investisseurs Informations Destinées Aux Actionnaires
BRIEF published on 04/28/2026 at 20:05, 4 months 14 days ago Mise à disposition du rapport financier annuel 2025 de Bogart AMF Rapport Financier Commissaires Aux Comptes Jacques Bogart Exercice 2025
BRIEF published on 04/28/2026 at 20:05, 4 months 14 days ago CYBERGUN reporte la publication de son Rapport financier annuel 2025 Comptes Consolidés Rapport Financier CYBERGUN Retard Publication AirSoft
BRIEF published on 04/28/2026 at 20:05, 4 months 14 days ago Availability of Bogart's 2025 Annual Financial Report AMF Financial Report Auditors Jacques Bogart Fiscal Year 2025
Published on 09/12/2026 at 02:35, 17 hours 40 minutes ago Gamma Resources Announces Extension of Private Placement Closing Date
Published on 09/11/2026 at 23:00, 21 hours 15 minutes ago Rio Grande Resources Engages Machai Capital for Investor Outreach
Published on 09/11/2026 at 22:05, 22 hours 10 minutes ago Usha Resources Announces Leadership Transition
Published on 09/11/2026 at 21:25, 22 hours 50 minutes ago Algo Grande Copper Intersects 30.23 Metres Grading 1.5% CuEq, including 3.55 Metres at 9.4% CuEq and 1.2-Metre Interval at 15.8% CuEq, 100 Metres Vertical Step-Out from Historical Intersects
Published on 09/11/2026 at 17:00, 1 day 3 hours ago Critical Elements Selected for Canada Investment Summit Prospectus, Showcasing Project to Leading Global Investors
Published on 09/12/2026 at 17:50, 2 hours 25 minutes ago New Delhi Marks UN Day for South-South Cooperation with Push to Scale Dryland Innovation Across the Global South
Published on 09/12/2026 at 07:30, 12 hours 45 minutes ago NAGRAVISION Secures Formula 1 Content for RTL Croatia and PRO PLUS Slovenia
Published on 09/11/2026 at 22:15, 22 hours ago Amrize Appoints Mario Gross as President of Building Envelope
Published on 09/11/2026 at 22:10, 22 hours 5 minutes ago Quantinuum to Participate in the Piper Sandler 5th Annual Growth Frontiers Conference
Published on 09/11/2026 at 19:44, 1 day ago DocMorris announces final conversion price and issue size of its New Convertible Bonds due 2031
Published on 09/11/2026 at 07:00, 1 day 13 hours ago BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/11/2026 at 07:00, 1 day 13 hours ago BIOPHYTIS ANNONCE LA RÉALISATION D’UNE AUGMENTATION DE CAPITAL DE 5,3 MILLIONS D’EUROS DESTINÉE À FINANCER SON ESSAI DE PHASE 2 DANS L’OBÉSITÉ
